AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation

Amyloid

Volumn 9, Issue 3, 2002, Pages 165-174

  Van Gameren, Ingrid I ^a   Hazenberg, Bouke P C ^a   Jager, Piet L ^a   Smit, Jan W ^a   Vellenga, Edo ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

AL amyloidosis; Autologous stem cell transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; ANTINEOPLASTIC AGENT; ETOPOSIDE; VAD COMBINATION;

ADULT; AMYLOIDOSIS; ARTICLE; AUTOTRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; MORTALITY; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCINTIGRAPHY; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; SURVIVAL; WEIGHT GAIN; MIDDLE AGED; SCINTISCANNING;

ADULT; AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; RADIONUCLIDE IMAGING; STEM CELL TRANSPLANTATION;

EID: 0036750157     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506120209114818     Document Type: Article

References (20)

1. Kyle RA and Gertz MA (1995). Primary systemic amyloidosis: Clinical and laboratory features in 474 Cases. Semin Hematol 32,45-59
2. Hawkins PN, Richardson S, MacSweeney JE, King AD, Vigushin DM, Lavender JP and Pepys MB (1993). Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. Q J Med 86, 365-374
3. Skinner M, Anderson JJ, Simms R, Falk R, Wang M, Libbey CA, Jones L, and Cohen AS (1996). Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine alone. Am J Med 100, 290-298
4. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ and Therneau TM (1997). A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone and colchicine. N Engl J Med 336, 1202-1207
5. Alexanian R and Dimoopoulos M. (1994). The treatment of multiple myeloma. N Engl J Med 330, 484-489
6. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, Lavalley M, O'Hara C, ArkinC, Wright DG and Skinner M (1998). Dose-intensive melphalan with blood stem-cell support for the treatment of AL (Amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 91, 3662-3670
7. Moreau P, Leblond V, Bourquelet P, Facon T, Huynh A, Caillot D, Hermine O, Attal M, Hamidou M, Nedellec G, Ferrant A, Audhuy B, Bataille R, Milpied N and Harousseau J (1998). Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Hematol 101, 766-769
8. Gertz MA, Lacy MQ, Gatineau DA, Inwards DJ, Chen MG, Tefferi A, Kyle RA and Litzow MR (2000). Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL) Bone Marrow Transplantation 26, 963-969
9. Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Lowenberg B, van Marwijk Kooy M, van Oers MH, Richel DJ, Schouten HC, Vellenga E, Verhoef GE, Wijemans PW, Wittebol S and Lokhorst HM (1999). Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first line treatment in untreated multiple myeloma. Br J Haematol 105, 127-130
10. Barlogie B, Smith L and Alexanian R (1984). Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310, 1353-1356
11. Reyners AK, Hazenberg BPC, Haagsma EB, Tio RA, Reitsma WD and Smit AJ (1998). The assessment of autonomic function in patients with systemic amyloidosis: methodological considerations. Amyloid Int J Exp Clin Invest 5, 193-199
12. Hovenga S, de Wolf JThM, Guikema JEJ, Klip H, Smit JW, Smit Sibinga CTh, Bos NA and Vellenga E (2000). Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Narrow Transplantation 25, 723-728
13. Hazenberg BPC, Limburg PC, Bijzet J and van Rijswijk MH (1999). A quantative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis. Ann Rheum Dis 58, 96-102
14. Jager PL, Hazenberg BPC, Franssen EJ, Limburg PC, van Rijswijk MH and Piers DA (1998). Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. J Nucl Med 39, 699-706
15. Hawkins PN, Lavender JP and Pepys MB (1990). Evaluation of systemic amyloidosis by scintigraphy with 123 I-labelled serum amyloid P component. N Engl J Med 323, 508-513
16. Gillmore JD, Lovat LB, Persey MR, Pepys MB and Hawkins PN (2001). Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358, 24-29
17. Mueller PS, Edwards WD and Gertz MA (2000). Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 109, 181-188
18. Comenzo RL (2000). Hematopoietic cell transplantation for primary systemic amyloidosis: What have we learned. Leuk Lymphoma 37, 245-258
19. Dispenzieri A, Lacy MQ, Kyle RA, Therneau TM, Larson DR, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust AL and Gertz MA (2001). Eligibilty for hematopoietic stem-cell transplantation for primary amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 19, 3350-3356
20. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ and Therneau TM (1999). Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 93, 1062-1066